Skip to main content
. 2024 Oct 21;9:488. Originally published 2024 Aug 19. [Version 2] doi: 10.12688/wellcomeopenres.22719.2

Table 5. Grading of local adverse events (adapted from 104).

Adverse event Grade Measurement
Pain/tenderness at
injection or biopsy site
0
1
2
3
No pain
Tender to touch only
Painful on movement
Persistent severe pain
at rest
Redness at injection or
biopsy site
0
1
2
3
0 mm
1–50 mm
51–100 mm
> 100 mm
Swelling at injection or
biopsy site
0
1
2
3
0 mm
1–20 mm
21–50 mm
> 50 mm
Scaling/pustule/nodule at
challenge site
0
1
2
3
0 mm
1–15 mm
16–29 mm
≥ 30 mm
Ulceration at challenge site 0
1
2
3
0 mm
1–9 mm
10–19 mm
≥ 20 mm, or ≥ 3 ulcers
at the challenge site
Scarring at challenge site 0
1
2
3
0 mm
1–9 mm
10–19 mm
≥ 20 mm

The following information will be documented for all adverse events: description, date of onset and end date, severity and any treatment or intervention undertaken. The severity of AEs will be assessed using the following scale: 1 = mild, 2 = moderate, 3 = severe.